10% off your first visit IV therapy & peptides to your door in Phoenix, 24/7.

What Is Stem Cell Therapy? What the Evidence Shows

Stem cell therapy covers two very different things: hospital blood stem cell transplants, which are established, and the IV infusions now widely advertised, which are still being studied. Here is what the research on those infusions has measured, where people run into trouble, and the questions to ask before you

Table of Contents

Stem cell therapy is often advertised as an IV infusion costing thousands of dollars, described in words like repair and regeneration. The same name also covers a treatment hospitals have relied on for decades to rebuild a person's blood and immune system after cancer treatment. Those are very different things, and the research behind them is very different too. Once you can tell them apart, and you know what the studies of IV infusions have actually measured, any offer you see becomes much easier to judge.

🔬

Is stem cell therapy proven?

For one use, yes. Blood stem cell transplants are an established hospital treatment for blood cancers and some immune disorders. Most other uses, including the IV infusions widely offered today, are still being studied. Trials of those infusions show a reasonable safety record so far, but their benefit has been inconsistent.

What a stem cell is, and why the type matters

A stem cell is a cell that can renew itself and develop into other kinds of cells. The National Institutes of Health groups them into three main types. Embryonic stem cells come from very early embryos and can become almost any cell in the body. Adult stem cells, also called tissue-specific stem cells, live in places like bone marrow and replace cells lost to wear, injury or disease. Induced pluripotent stem cells are ordinary adult cells reprogrammed in a lab to behave like embryonic ones.

The type sets the limits. Adult stem cells generally make the cells of the tissue they came from, so a blood-forming stem cell makes blood cells, not cartilage or nerve. That biology is behind one of the plainest points the International Society for Stem Cell Research (ISSCR) makes to patients: the same stem cell treatment is very unlikely to work for diseases affecting different tissues and organs.

In practice, stem cell therapy means putting cells, or cells grown from them, into the body to replace damaged tissue or change how it behaves. The adult stem cells most commonly used in regenerative medicine are mesenchymal stromal cells, also called mesenchymal stem cells, which can be taken from bone marrow, fat or umbilical cord tissue.

The one established use, and the many still being studied

Medical and scientific sources draw a clear line between two groups of stem cell treatments, and the first thing worth knowing about any offer is which group it belongs to.

Established: blood stem cell transplants

Given in hospitals for blood cancers such as leukemia, lymphoma and myeloma, and for some immune and blood disorders. The ISSCR describes blood stem cell transplantation as well established and effective.

Still being studied: most other uses

Infusions and injections offered for a wide range of conditions belong here. The ISSCR's position is that, apart from blood stem cell transplants and a small number of other uses, stem cell treatments are still being tested, and that testing a treatment in trials does not guarantee it becomes an established therapy.

What the research on IV infusions has measured

The largest safety review of these infusions, published in EClinicalMedicine in 2020, pooled 55 randomized trials covering 2,696 adults who received mesenchymal cells into a vein or artery, compared with people who did not. Fever was more common after the cells. Across those trials, the researchers found no significant increase in other immediate infusion reactions, infections, blood clots, deaths or cancers, and no trial was stopped early for safety reasons.

That is a meaningful finding, with limits worth keeping in view. These were controlled trials with screened patients, defined products and medical teams watching for problems, and they measured whether the infusions caused harm. Whether they helped is a separate question, and so far the answer is mixed. Reviews in Science Advances (2020) and Molecular Therapy (2025) describe safety as consistent but benefit as inconsistent, with many trials missing their main efficacy goal. The condition where these cells have been studied most is graft-versus-host disease, a complication that can follow a blood stem cell transplant. The IV line itself follows the same basics as any drip, and we cover how IV therapy safety works separately.

Results also vary because these products are not interchangeable. Cells from bone marrow, fat and umbilical cord behave differently, and the donor, the growing conditions and the storage change them further. A result reported for one product says little about another.

Where people run into trouble

Serious harm has been reported outside clinical trials. A 2018 review in Stem Cells Translational Medicine collected published cases of complications after unproven stem cell interventions, and a 2021 report in JAMA Network Open described bacterial infections among people given umbilical cord blood products that had been marketed as stem cell treatment. Cases like these are why the questions below start with the product itself: what it is, who made it and how it was checked.

Using your own cells does not remove the risk. The ISSCR points out that collecting cells, processing or growing them, and putting them back can introduce contamination or change how the cells behave, and that cells can end up somewhere they do not belong.

Person writing questions in a notepad at a kitchen table before booking treatment

Questions to ask any provider before you book

  • What exactly is the product: which cell type, from which tissue, and from a donor or from me?
  • Who makes it, and how is each batch checked for contamination?
  • What published research exists for my specific condition, and did it come from a controlled trial?
  • Which side effects have your patients had, and what happens if I have one during or after the infusion?
  • Who reviews my medical history beforehand, and who stays with me during the infusion?
  • What result should I watch for, and when would we expect to see it?
  • What is the total cost, and what does it include?

How Stem Cell is offered at Phoenix Mobile IV Therapy

Phoenix Mobile IV Therapy offers Stem Cell as a 60-minute session for $4,999. Unlike most of the menu, it is not booked online. It starts with a good-faith exam, arranged by calling (480) 908-9266, and that call is a good time to ask the questions above. Like every visit we make, the session takes place at your home, hotel or office; here is what an at-home visit looks like. The session details are on our Stem Cell service page.

Common questions about stem cell therapy

Can I join a clinical trial instead of paying for treatment?

Sometimes. Responsibly run clinical trials have independent ethics oversight, are listed on public registries, compare the treatment against a control group, and generally do not charge participants for the treatment being tested. Ask your doctor or specialist whether a trial fits your condition; ClinicalTrials.gov lists studies by condition and location.

Why do patient stories about stem cell treatment sound so positive?

Because a story cannot separate the treatment from everything else going on. The ISSCR notes that people can feel better because they expect to, because of other treatments or lifestyle changes made at the same time, or because many conditions naturally have good and bad stretches. Controlled trials exist to tell those apart.

Why do clinics say stem cells reduce inflammation?

The idea comes largely from lab and animal studies, where mesenchymal cells repeatedly calmed inflammation and helped tissue heal. In people, results have been far less consistent, and reviews describe several large trials that did not meet their main goals. A promising lab result is a reason to study something, not proof it works in patients.

Should I stop my current treatment if I try stem cell therapy?

No change to your current care should happen without the clinician who prescribed it. Tell every clinician involved, including your primary care doctor, about any cell treatment you are considering, so that your medicines, test results and follow-up can be read with the full picture in mind.

How can I tell whether a treatment helped me?

Agree before the session, with the clinician offering it, on what you will measure and when: a symptom score, a lab value, or a daily activity that matters to you. Keep a simple record for a few weeks before and after, because many conditions rise and fall on their own.

Talk through Stem Cell before you book
Stem Cell starts with a good-faith exam. Call to ask your questions and set it up.
Call (480) 908-9266

Where we come to you

Phoenix Mobile IV Therapy comes to homes, hotels and offices across the Phoenix metro and the wider Valley.

Sources

  • National Institutes of Health, "Stem Cell Basics." stemcells.nih.gov
  • International Society for Stem Cell Research, "Types of Stem Cell Treatments." aboutstemcells.org
  • International Society for Stem Cell Research, "9 Things to Know About Stem Cell Treatments." aboutstemcells.org
  • Duarte RF et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Bone Marrow Transplantation, 2019. doi:10.1038/s41409-019-0516-2
  • Thompson M et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine, 2020. doi:10.1016/j.eclinm.2019.100249
  • Levy O et al. Shattering barriers toward clinically meaningful MSC therapies. Science Advances, 2020. doi:10.1126/sciadv.aba6884
  • Lu W et al. Mesenchymal stromal cell therapy: progress to date and future outlook. Molecular Therapy, 2025. doi:10.1016/j.ymthe.2025.02.003
  • Caplan HW et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Frontiers in Immunology, 2019. doi:10.3389/fimmu.2019.01645
  • Kadri N et al. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cellular and Molecular Immunology, 2023. doi:10.1038/s41423-023-01022-z
  • Squillaro T et al. Clinical trials with mesenchymal stem cells: an update. Cell Transplantation, 2016. doi:10.3727/096368915X689622
  • Česnik AB, Švajger U. The issue of heterogeneity of MSC-based advanced therapy medicinal products: a review. Frontiers in Cell and Developmental Biology, 2024. doi:10.3389/fcell.2024.1400347
  • Bauer G et al. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Translational Medicine, 2018. doi:10.1002/sctm.17-0282
  • Hartnett KP et al. Investigation of bacterial infections among patients treated with umbilical cord blood-derived products marketed as stem cell therapies. JAMA Network Open, 2021. doi:10.1001/jamanetworkopen.2021.28615

Share this Article

Table of Contents

Last Updated: November 3, 2026

Related Blogs